Market Research Report
Asia-Pacific Hospital-Acquired Infection Diagnostics Market By Product By Infection Type, By Test Type and End Use : Global Opportunity Analysis and Industry Forecast, 2020-2027
|Asia-Pacific Hospital-Acquired Infection Diagnostics Market By Product By Infection Type, By Test Type and End Use : Global Opportunity Analysis and Industry Forecast, 2020-2027|
Published: December 31, 2020
Allied Market Research
Content info: 228 Pages
Delivery time: 2-3 business days
Asia-Pacific Hospital-Acquired Infection Diagnostics Market By Product (Instrument and Reagents & Consumables) By Infection Type (Procedural Sedation, Pain Management, Emergency Medicine, Critical Care, General Floor, and Others), By Test Type (Molecular Diagnostics, Urinalysis, And Immunoassay) and End Use (Hospitals, Clinics and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027.
The Asia-Pacific hospital-acquired infection diagnostics market accounted for $418.937 million in 2019, and is expected to reach $780.882 million by 2027, registering a CAGR of 7.5% from 2020 to 2027.
Hospital-acquired infections (HAIs) are the infections caused by bacterial, viral, and fungal pathogens. These infections can be acquired in clinical settings, such as nursing home, rehabilitation facility, outpatient clinic, or other clinical settings. They can either be acquired from an infected patient, outside environment, or from the staff of that facility. The market is primarily driven by the increase in incidences of infections caused in clinical settings, especially in developing economies owing to their poor hygiene facilities.
The majority of HAI are caused by bacteria already present in the patient's body prior to the infection, and may lead to cross-transmission between patients or between patients and healthcare professionals. The environment in a healthcare facility can also be a source of infection, with microorganism spread through air, water or surfaces. Patients in health facilities are more vulnerable than the general population due to underlying illness, greater fragility (such as for premature babies, the elderly, and immunocompromised patients), and exposure to invasive medical procedures. However, the increase in healthcare cost and prevalence of antibiotic resistant infections impedes the market growth.
Other factors contributing to infectious disease in hospitals include patients with contagious illnesses and patient exposure to infectious bodily fluids and other medical waste.
Furthermore, routine medical procedures, such as surgery, intubation and catheter placement, can allow infectious agents to enter the body. Hence, boost the Asia-Pacific hospital-acquired infection diagnostics market growth.
Country wise, the market is analyzed across India, Nepal, Bhutan, Bangladesh, Maldives, Sri Lanka, Myanmar, and Rest of Asia-Pacific. India accounted for the largest market share in 2019, and is expected to retain its dominance throughout the forecast period. This is attributed to the factors such as increase in prevalence of nosocomial infections, such as surgical site infections and blood stream infections. According to Indian Journal of Basic and Applied Medical Research, India reported an overall growth rate for hospital acquired infections of 4.4% after conducting a research on 10,835 patients in various clinical settings. Furthermore, Sri Lanka and Myanmar is anticipated to expand at a significant CAGR of 8.3% during the forecast period, owing to expeditiously improving healthcare systems and rise in healthcare expenditure and awareness regarding hospital-acquired infections.
The market is segmented on the basis of product, test type, infection type, end user, and country. By product, the market is bifurcated into instrument and reagents & consumables. By test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. By infection type, it is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal Infections, urinary tract infections (UTI), and others.
The key players operating in the Asia-Pacific hospital-acquired infection diagnostics market include BECTON, DICKINSON AND COMPANY, Cepheid, Abbott Laboratories, F. Hoffmann-LA Roche Ltd, AstraZeneca, Daiichi Sankyo Co., Ltd., Hologic, Inc., Siemens, BIOMERIEUX SA, NG Biotech.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing market opportunities.
The key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product type
By Test Type
By Infection Type
By End User